In 680 participants with high-risk resected head and neck squamous cell carcinoma, adding nivolumab to postoperative cisplatin and radiotherapy improved disease-free survival (HR 0.76; 666 analysed). Treatment-related grade 4 events: 10% vs 5%.
RCTn = 680
Bourhis et al. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial